Exploring The Mechanism Of Action Of The Combination Of Oleanolic Acid And Aspirin In The Treatment Of Colorectal Cancer

Abstract

Colorectal cancer (CRC) is one of the common malignancies, and the drug resistance and severe toxicity generated by long-term chemotherapy in colorectal cancer patients severely limit the efficiency of chemotherapy for colorectal cancer. Aspirin is currently one of the most promising chemopreventive drugs for CRC, but its long-term use is prone to side effects such as gastrointestinal bleeding, which limits its clinical application. Oleanolic acid is an effective anti-tumor drug, which can inhibit the proliferation of many kinds of colorectal cancer cells in colorectal cancer. Therefore, this study was designed to investigate the potential mechanism of action of the combination of oleanolic acid and aspirin against colorectal cancer through in vitro experiments. The results of cellular assays showed that oleanolic acid and aspirin inhibited the proliferation of HT-29 and HCT-116 cells, and oleanolic acid dose-dependently inhibited the expression of PTGS2 in HT-29 cells and enhanced the expression of PTGS2 and inhibited the degradation of IκBα in colorectal cancer cells by aspirin. This study reports for the first time the antinovel combination of oleanolic acid and aspirin against colorectal cancer. It provides a new direction for the development of new drugs for the treatment of colorectal cancer.